Article Sidebar
Published:
Oct 3, 2018Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Picroside I inhibits asthma phenotypes by regulating Tbet/ GATA-3 ratio and Th1/Th2 balance in a murine model of asthma
Abstract
Purpose: To examine the anti-asthmatic activity of picroside I in murine asthma model, and to elucidate the mechanism(s) involved.
Methods: The study involved systematic sensitization of acclimatized BALB/c mice with ovalbumin (OVA), and subsequent exposure to aerosol allergens. The effect of picroside I on associated IgE formation was determined. All assays were performed using standard protocols. Protein expression was assessed using western blotting.
Results: Picroside I inhibited allergic airway inflammation, AHR, and the production of OVA-associated IgE and Th2 cytokines. Moreover, it altered the T-bet/GATA3 ratio by suppressing the phosphorylation of STAT6 in a dose-dependent manner.
Conclusion: These results indicate that the anti-asthmatic effect of picroside I occurs via a mechanism involving inhibition of Th2 cytokines by suppression of the expressions of pSTAT6 and GATA-3, and upregulation of the expression of T-bet. Thus, picroside I is a promising agent for the management of asthma.
Keywords: Picroside, Asthma, Allergic response, IgE, GATA-3, pSTAT6
